Merki-Feld, Gabriele S. http://orcid.org/0000-0002-8644-773X
Sandor, Peter S.
Nappi, Rossella E.
Pohl, Heiko
Schankin, Christoph
Funding for this research was provided by:
Universität Zürich
Article History
Received: 26 January 2021
Accepted: 10 April 2021
First Online: 29 April 2021
Declarations
:
: GS Merki had financial relationship (lecturer, member of advisory boards and/or consultant) with Bayer, MSD, Novartis, Exeltis. These companies are not involved in the present manuscript. PS Sandor has received honoraria for advisory boards, consulting, and as a speaker, within the past 5 years, from Novartis, Eli Lilly, TEVA Pharmaceuticals, Allergan, Almirall, Amgen, MindMed, and Grünenthal. These companies are not involved in the present manuscript. RE Nappi had a financial relationship (lecturer, member of advisory boards and/or consultant) with Bayer HealthCare, Endoceutics, Exceltis, FIDIA, Gedeon Richter, MSD, Novo Nordisk, Palatin, Pfizer, Shionogi, Theramex. These companies are not involved in the present manuscript. H Pohl declares no COI. C Schankin has received honoraria from Novartis, Eli Lilly, TEVA Pharmaceuticals, Allergan, Almirall, Amgen, MindMed, and Grünenthal. These companies are not involved in the present manuscript.
: Approval for the course of the study and the applied documents was given by the cantonal ethics committee of Zurich (KEK-stV-Nr 2016-01791). Written consent from the participants was obtained.